What are Activin receptor ligand trap drugs?

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Activin receptor ligand trap drugs are pharmacologic agents that share a common mechanism (typically targeting Activin type II receptor). 0 are currently marketed, with 2 more in clinical development.

Activin receptor ligand trap

0 marketed 1 in Phase 3 1 in Phase 2

This page covers all Activin receptor ligand trap drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Activin type II receptor, Activin receptor type IIA (ActR2A).

Targets

Activin type II receptor · Activin receptor type IIA (ActR2A)

Phase 3 pipeline (1)

ACE-536 · Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA · Hematology
ACE-536 is an activin receptor ligand trap that inhibits activin signaling to promote erythropoiesis and increase hemoglobin levels.

Phase 2 pipeline (1)

ACE-011 · Celgene · Hematology/Oncology
ACE-011 is an activin receptor type IIA ligand trap that inhibits activin signaling to promote erythropoiesis and increase hemoglobin levels.

Patent intelligence

activin receptor ligand trap patent landscape — aggregated cliff calendar, attackable patents, originator estates